Abemaciclib | List of Frontiers open access articles

Original Research

Published on 23 Jun 2022

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells

in Pharmacology of Anti-Cancer Drugs

Chao-Yue Sun
Milton Talukder
Di Cao
Cun-Wu Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2022.829759

5,227 views
12 citations

Original Research

Published on 17 Jun 2025

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon

in Breast Cancer

Anwar Al Nouri
Faisal Al Terkait
Nagi El Saghir
Hady Ghanem
Joseph Kattan
Cynthia Bishouti
Jade Dreyer
Soniya Rai
Alexandru Rosca

Frontiers in Oncology

doi 10.3389/fonc.2025.1437380

3,459 views

Original Research

Published on 01 Jul 2024

Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells

in Cancer Molecular Targets and Therapeutics

Aurora Costa
Iris Maria Forte
Francesca Pentimalli
Carmelina Antonella Iannuzzi
Luigi Alfano
Francesca Capone
Rosa Camerlingo
Alessandra Calabrese
Claudia von Arx
Reyes Benot Dominguez

Frontiers in Oncology

doi 10.3389/fonc.2024.1418951

3,978 views
5 citations

Case Report

Published on 09 Jan 2023

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review

in Breast Cancer

Yan Mao
Meng Lv
Yongmei Wang
Weihong Cao
Wenfeng Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1022913

4,539 views
1 citation

Clinical Trial

Published on 26 Oct 2020

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

in Thoracic Oncology

Jonathan W. Goldman
Julien Mazieres
Fabrice Barlesi
Konstantin H. Dragnev
Marianna Koczywas
Tuncay Göskel
Alexis B. Cortot
Nicolas Girard
Claas Wesseler
Helge Bischoff

Frontiers in Oncology

doi 10.3389/fonc.2020.578756

13,532 views
49 citations

Original Research

Published on 12 Mar 2025

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

in Breast Cancer

Sara M. Tolaney
Komal Jhaveri
Teresa Helsten
Shannon L. Puhalla
Alison Conlin
E. Claire Dees
Muralidhar Beeram
Sonya C. Chapman
Andrew Lithio
Lacey M. Litchfield

Frontiers in Oncology

doi 10.3389/fonc.2025.1555921

5,616 views

Original Research

Published on 22 Jul 2022

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

in Pharmacology of Anti-Cancer Drugs

Graziana Digiacomo
Claudia Fumarola
Silvia La Monica
Mara Bonelli
Andrea Cavazzoni
Maricla Galetti
Rita Terenziani
Kamal Eltayeb
Francesco Volta
Silvia Zoppi

Frontiers in Oncology

doi 10.3389/fonc.2022.942341

6,644 views
18 citations

Original Research

Published on 31 Mar 2025

Survival benefit from abemaciclib in non–small cell lung cancer by Kirsten rat sarcoma–mutation gene expression subtype: retrospective analysis from the JUNIPER Trial

in Thoracic Oncology

Jiangang Liu
Hong Wang
Amit Aggarwal
Maria Jesus Ortiz-Ruiz
Elisabet Zapatero-Solana
Maria Jose Lallena
Sandra Peregrina
Gloria Martinez del Hoyo
Susana Velasco
Philip J. Ebert

Frontiers in Oncology

doi 10.3389/fonc.2025.1461530

3,180 views

Original Research

Published on 10 May 2023

Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation

in Experimental Pharmacology and Drug Discovery

Yanting Zhou
Xiandeng Li
Peifang Luo
Huiting Chen
Yan Zhou
Xueting Zheng
Yuan Yin
Haoche Wei
Hongji Liu
Wen Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1154654

5,656 views
4 citations

Case Report

Published on 27 Aug 2025

Case Report: Relapsed alveolar rhabdomyosarcoma treated with abemaciclib, temozolomide, and irinotecan in the JPCS study

in Pediatric Oncology

Antonio Juan Ribelles
Nuria Benavent
Daniel Sanchez Mateos
Celine Pitou
Yanhong Zhou
Molly C. Hardebeck
Holly Knoderer
Adela Cañete

Frontiers in Oncology

doi 10.3389/fonc.2025.1637177

4,072 views

Original Research

Published on 08 Sep 2025

Cost-effectiveness analysis of CDK4/6 inhibitors in the second-line treatment for HR+/HER2− advanced or metastatic breast cancer

in Pharmacology of Anti-Cancer Drugs

Kaixuan Wang
Shixian Liu
Shunping Li
Jie Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1540088

2,786 views
2 citations

Original Research

Published on 10 Feb 2022

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

in Breast Cancer

Sara M. Tolaney
Muralidhar Beeram
J. Thaddeus Beck
Alison Conlin
E. Claire Dees
Shannon L. Puhalla
Brent N. Rexer
Howard A. Burris
Komal Jhaveri
Teresa Helsten

Frontiers in Oncology

doi 10.3389/fonc.2021.810023

13,245 views
16 citations

Original Research

Published on 23 Jun 2022

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

in Pharmacology of Anti-Cancer Drugs

Dongcheng Liu
Hongguang Liu
Jiadi Gan
Shinuan Zeng
Fuhua Zhong
Bin Zhang
Zhe Zhang
Siyu Zhang
Lu Jiang
Guangsuo Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.918317

7,046 views
12 citations

Original Research

Published on 20 Jun 2025

Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy

in Cancer Molecular Targets and Therapeutics

Xianghua Quan
CaiHong Sun
Bing Han
ChuanZhou Zhang
HuaiQin Cang
Xiaomin Xing
Qie Guo

Frontiers in Oncology

doi 10.3389/fonc.2025.1529980

3,274 views
1 citation

Case Report

Published on 23 Jan 2024

Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review

in Breast Cancer

Nuno Rodrigues Alves
Ana Filipa Duarte
David Fernandes Ribeiro
Rita Sousa Silva
Bruno Almeida Carvalho
Diogo Alpuim Costa

Frontiers in Oncology

doi 10.3389/fonc.2024.1286910

5,649 views
4 citations

Original Research

Published on 24 Jul 2024

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

in Breast Cancer

Shereen Elazzazy
Nour Hisham Al-Ziftawi
Mohamed Izham Mohamed Ibrahim
Salha Bujassoum
Anas Hamad

Frontiers in Oncology

doi 10.3389/fonc.2024.1413676

6,078 views
5 citations

Articles

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon

Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

Survival benefit from abemaciclib in non–small cell lung cancer by Kirsten rat sarcoma–mutation gene expression subtype: retrospective analysis from the JUNIPER Trial

Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation

Case Report: Relapsed alveolar rhabdomyosarcoma treated with abemaciclib, temozolomide, and irinotecan in the JPCS study

Cost-effectiveness analysis of CDK4/6 inhibitors in the second-line treatment for HR+/HER2− advanced or metastatic breast cancer

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy

Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation